Market Overview
According to Fortune Business Insights, the global chronic kidney disease market size was valued at USD 90.41 billion in 2025. The market is projected to grow from USD 96.33 billion in 2026 to USD 160.02 billion by 2034, exhibiting a CAGR of 6.55% during the forecast period. North America dominated the chronic kidney disease market in 2025.
Fortune Business Insights™ has deep-dived into these insights in its latest research report, titled “Chronic Kidney Disease Market, 2026-2034.”
The analysis shows that the market is witnessing significant growth due to the increasing incidence of chronic kidney disease (CKD), alongside rising rates of diabetes, high blood pressure, and diagnostics globally. For example, according to data published by The Professional Society for Health Economics and Outcomes Research (ISPOR) in 2023, an estimated 3.25 million adults in the U.K. are suffering from chronic kidney disease. This trend, coupled with a growing number of drug candidates in the pipeline, indicates a strong demand for CKD treatments worldwide.
Major Players Profiled in the Market Report:
Segments
Widespread Use as a First-Line Treatment to Propel ACE Inhibitors Segment Growth
Based on drug class, the market is divided into ACE inhibitors, angiotensin-II receptor blockers, calcium channel blockers, beta-blockers, erythropoiesis-stimulating agents (ESAs), diuretics, and others. The ACE inhibitors segment accounts for a significant revenue share and dominates the market owing to its widespread use as a first-line treatment for CKD—particularly in patients with hypertension and diabetic nephropathy—to reduce blood pressure, lower proteinuria, and prevent end-stage renal disease.
High Convenience and Self-Administration to Drive Oral Segment Expansion
By route of administration, the market is categorized into oral and parenteral. The oral segment is leading the market as there is a high preference for oral medications due to their convenience, increasing demand for self-administration options among patients, and frequent new product launches, such as Zydus Lifesciences' oral medication, Oxemia.
Hospital Pharmacies to Dominate the Market Due to Rising Hospital Diagnoses
Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment holds a significant market share owing to patient convenience, the easy availability of drugs, and the growing number of global CKD cases that require hospitalization and initial diagnosis in hospital settings.